Edwards Lifesciences - EW Stock Forecast, Price & News

24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 5 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EW shares.
View EW analyst ratings or view top-rated stocks.

24 equities research analysts have issued 12 month price objectives for Edwards Lifesciences' stock. Their EW share price forecasts range from $73.00 to $144.00. On average, they anticipate the company's stock price to reach $107.29 in the next year. This suggests a possible upside of 40.5% from the stock's current price.
View analysts price targets for EW or view top-rated stocks among Wall Street analysts.

Edwards Lifesciences' stock was trading at $129.55 at the start of the year. Since then, EW stock has decreased by 41.1% and is now trading at $76.36.
View the best growth stocks for 2022 here.

Edwards Lifesciences saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 8,110,000 shares, an increase of 8.9% from the October 15th total of 7,450,000 shares. Based on an average daily trading volume, of 3,730,000 shares, the short-interest ratio is presently 2.2 days. Currently, 1.3% of the company's shares are short sold.
View Edwards Lifesciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, January 25th 2023.
View our EW earnings forecast.

Edwards Lifesciences Co. (NYSE:EW) posted its quarterly earnings data on Wednesday, October, 27th. The medical research company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.53 by $0.01. The medical research company had revenue of $1.31 billion for the quarter, compared to analysts' expectations of $1.32 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 24.75% and a net margin of 27.20%. The business's quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.51 earnings per share.
Read the conference call transcript.

Edwards Lifesciences's stock split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were issued to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Edwards Lifesciences issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share (EPS) guidance of $2.40-$2.50 for the period, compared to the consensus EPS estimate of $2.51. The company issued revenue guidance of $5.35 billion-$5.35 billion, compared to the consensus revenue estimate of $5.47 billion.

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.48%), Vanguard Group Inc. (8.23%), State Street Corp (4.34%), Bank of New York Mellon Corp (3.28%), Alliancebernstein L.P. (2.78%) and Brown Advisory Inc. (2.30%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends.

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EW stock can currently be purchased for approximately $76.36.

Edwards Lifesciences (NYSE:EW) has a market capitalization of $47.21 billion and generates $5.23 billion in revenue each year. The medical research company earns $1.50 billion in net income (profit) each year or $2.32 on an earnings per share basis.

The company employs 15,700 workers across the globe.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525.